Overweight, obesity, and cardiovascular disease in heterozygous familial hypercholesterolaemia: the EAS FH Studies Collaboration registry.

Background And Aims: Overweight and obesity are modifiable risk factors for atherosclerotic cardiovascular disease (ASCVD) in the general population, but their prevalence in individuals with heterozygous familial hypercholesterolaemia (HeFH) and whether they confer additional risk of ASCVD independent of LDL cholesterol (LDL-C) remains unclear.

Methods: Cross-sectional analysis was conducted in 35 540 patients with HeFH across 50 countries, in the EAS FH Studies Collaboration registry. Prevalence of World Health Organization-defined body mass index categories was investigated in adults (n = 29 265) and children/adolescents (n = 6275); and their association with prevalent ASCVD.

Exploring emerging pharmacotherapies for type 2 diabetes patients with hypertriglyceridemia.

Introduction: Atherogenic dyslipidaemia with increased triglycerides, low high-density lipoprotein cholesterol levels and increased small dense low-density lipoprotein (LDL) particles is a major risk factor contributing to the increased cardiovascular (CV) risk in patients with type 2 diabetes (T2D). This is regarded as a residual risk after achieving target levels of LDL cholesterol.

Areas Covered: This article reviews the novel therapies to reduce triglycerides in patients with T2D.

Advances in statin adverse reactions and the potential mechanisms: A systematic review.

Background: Elevated low-density lipoprotein (LDL) cholesterol is a major risk factor for cardiovascular disease. Statins are the cornerstone of preventing and treating cardiovascular disease and can reduce LDL cholesterol by more than 60%. Although statins have high tolerability and safety, as the number of users increases, their adverse reactions in the liver, kidneys, skeletal muscles, and their potential to induce diabetes have also received widespread attention.

An up-to-date review of emerging biologic therapies for hypercholesterolemia.

Introduction: Hypercholesterolemia and other lipid disorders are major causes of atherosclerotic cardiovascular disease (ASCVD). Statins have been the mainstay of lipid-lowering therapy for many years, but they may not be adequate to achieve the target low-density lipoprotein (LDL) cholesterol levels and there are other residual lipid risk factors.

Areas Covered: This article reviews the biologic therapies in development for hypercholesterolemia identified by a PubMed search.

Key factors related to happiness and anxiety in Aotearoa New Zealand during the COVID-19 pandemic.

Aim: Mental wellbeing has been one of the most prominent health concerns in Aotearoa New Zealand and has only been exacerbated by the COVID-19 pandemic. Here we explored factors associated with anxiety and happiness in a mid-pandemic climate in Aotearoa.

Methods: Analyses were performed on the anxiety and happiness scores from the wellbeing survey in December 2020 (Statistics NZ Tatauranga Aotearoa; 30,000 responders contacted for the Household Labour Force Survey).